Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business. More @Wikipedia
Hover over any link to get a description of the article. Please note that search keywords are sometimes hidden within the full article and don't appear in the description or title.